Teva Pharmaceutical Industries Limited (NYSE:TEVA) Receives $20.88 Consensus Target Price from Brokerages

Teva Pharmaceutical Industries Limited (NYSE:TEVA - Get Free Report) has been given an average recommendation of "Moderate Buy" by the eight brokerages that are covering the firm, Marketbeat.com reports. Two investment analysts have rated the stock with a hold rating and six have given a buy rating to the company. The average 12-month target price among brokerages that have issued ratings on the stock in the last year is $20.88.

A number of analysts have commented on TEVA shares. JPMorgan Chase & Co. lifted their target price on Teva Pharmaceutical Industries from $16.00 to $18.00 and gave the stock a "neutral" rating in a report on Monday, October 21st. StockNews.com lowered Teva Pharmaceutical Industries from a "strong-buy" rating to a "buy" rating in a research report on Wednesday. Barclays raised their price target on shares of Teva Pharmaceutical Industries from $25.00 to $28.00 and gave the company an "overweight" rating in a report on Wednesday. Finally, UBS Group boosted their price objective on shares of Teva Pharmaceutical Industries from $24.00 to $26.00 and gave the company a "buy" rating in a report on Tuesday, September 3rd.

Teva Pharmaceutical Industries Stock Up 0.5 %

Shares of TEVA traded up $0.11 on Thursday, hitting $21.31. 14,443,077 shares of the stock traded hands, compared to its average volume of 9,431,179. Teva Pharmaceutical Industries has a one year low of $10.34 and a one year high of $21.98. The company has a market capitalization of $24.14 billion, a PE ratio of -25.07, a P/E/G ratio of 0.99 and a beta of 0.79. The business has a 50 day simple moving average of $17.61 and a 200 day simple moving average of $17.45. The company has a debt-to-equity ratio of 2.57, a quick ratio of 0.61 and a current ratio of 0.89.

Insider Buying and Selling at Teva Pharmaceutical Industries

In related news, EVP Christine Fox sold 19,388 shares of Teva Pharmaceutical Industries stock in a transaction on Wednesday, November 20th. The shares were sold at an average price of $16.87, for a total transaction of $327,075.56. Following the transaction, the executive vice president now owns 44,104 shares in the company, valued at approximately $744,034.48. The trade was a 30.54 % decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. 0.55% of the stock is currently owned by corporate insiders.

Hedge Funds Weigh In On Teva Pharmaceutical Industries

Large investors have recently made changes to their positions in the business. UMB Bank n.a. lifted its holdings in Teva Pharmaceutical Industries by 555.6% in the 3rd quarter. UMB Bank n.a. now owns 2,439 shares of the company's stock worth $44,000 after purchasing an additional 2,067 shares in the last quarter. Smithfield Trust Co lifted its holdings in shares of Teva Pharmaceutical Industries by 55.7% in the third quarter. Smithfield Trust Co now owns 2,739 shares of the company's stock worth $50,000 after buying an additional 980 shares in the last quarter. Wilmington Savings Fund Society FSB bought a new position in shares of Teva Pharmaceutical Industries during the third quarter worth $50,000. Claro Advisors LLC purchased a new position in Teva Pharmaceutical Industries during the third quarter valued at $52,000. Finally, Venturi Wealth Management LLC bought a new stake in Teva Pharmaceutical Industries in the 3rd quarter valued at $60,000. 54.05% of the stock is currently owned by hedge funds and other institutional investors.

Teva Pharmaceutical Industries Company Profile

Teva Pharmaceutical Industries Limited develops, manufactures, markets, and distributes generic medicines, specialty medicines, and biopharmaceutical products in North America, Europe, Israel, and internationally. It offers generic medicines in various dosage forms, such as tablets, capsules, injectables, inhalants, liquids, transdermal patches, ointments, and creams; sterile products, hormones, high-potency drugs, and cytotoxic substances in parenteral and solid dosage forms; and generic products with medical devices and combination products.